FDA Releases Final Label Revision And TA ANDA Amendment Guidances

The FDA Aims To Improve The Development, Review, And Approval Process Of Generic Drugs

 
• By Urtė Fultinavičiūtė
  
Sign outside of FDA's headquarters in White Oak, MD
The two new guidances are part of the Drug Competition Action Plan • Source: Alamy

More from Generics

More from Products